COA Submits Comments on CMS' Proposed CAR T-Cell Coverage Decision
The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy.
The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy, saying that while they are pleased with the direction of covering the therapy, they have concerns with the language included in the memo.
According to COA, CMS should not limit CAR T-cell coverage to hospitals, with many community oncology practices having the experience and capability to administer the therapy. Read the
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Bariatric Surgery Potentially Superior to GLP-1 RA Treatment for Obesity
September 17th 2025
- Transforming Addiction Care: From Stigma to Support
September 16th 2025
- Value-Based Care Veterans, Surprised by EOM Results, Ponder Next Move
September 11th 2025